Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation”

3 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 3 results

Testing effectiveness (Phase 2)Looking for participantsNCT06008288
What this trial is testing

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Who this might be right for
KRAS P.G12CPancreatic CancerSolid Tumor
Allist Pharmaceuticals, Inc. 88
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06435455
What this trial is testing

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
Suzhou Genhouse Bio Co., Ltd. 126
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07468071
What this trial is testing

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerAdvanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals 40